for Health Care Providers
Table 4. SVR rates in genotype 1-infected patients treated with PegIFN/RBV +/- BOC or TVR
Therapy against Hepatitis C in Patients with Genotype 1 Infection
| Study cohort, N | SVR to PI/PegIFN/RBV (arm 1 of trial) | SVR to PI/PegIFN/RBV (arm 2 of trial) | SVR with PegIFN/RBV |
|---|---|---|---|
| BOC, boceprevir; eRVR, extended rapid virologic response; HCV, hepatitis C virus; PegIFN, peginterferon alfa; PI, protease inhibitor; RBV, ribavirin; RGT, response-guided therapy; SVR, sustained virologic response; TVR, telaprevir. | |||
| Treatment-naive | |||
| BOC (SPRINT-2), SVR% | 63 | 66 | 38 |
| N = 1,099 (11) | BOC/PegIFN/RBV RGT | BOC/PegIFN/RBV 44 weeks | PegIFN/RBV 48 weeks |
| TVR (ADVANCE), SVR% | 69 | 75 | 44 |
| N = 1,088 (12) | TVR for 8 weeks/PegIFN/RBV RGT | TVR for 12 weeks/PegIFN/RBV RGT | PegIFN/RBV 48 weeks |
| TVR (ILLUMINATE), SVR% | 71 | 73 | NA |
| N = 540 (49) | TVR for 12 weeks/PegIFN/RBV (24 total weeks) if eRVR | TVR for 12 weeks/PegIFN/RBV(48 total weeks) if eRVR | - |
| Treatment-experienced | |||
| TVR (REALIZE), SVR% overall | - | - | |
| N = 662 (13) | NA | 64-66 | 17 |
| TVR for 12 weeks/PegIFN/RBV (48 weeks total) | |||
| Prior relapsers (SVR%) | - | 83-88 | 24 |
| Prior partial responders (SVR%) | - | 54-59 | 15 |
| Prior null responders (SVR%) | - | 29-33 | 5 |
| BOC (RESPOND-2), SVR% overall | |||
| N = 403 (14) | 59 | 66 | 21 |
| BOC/PegIFN/RBV (48 weeks total) | |||
| Prior relapsers (SVR%) | 69 | 75 | 29 |
| Prior partial responders (SVR%) | 40 | 52 | 7 |
